Project Grant R00AR082987
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$249K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine. This grant will fund the development and characterization of recombinant, cell-penetrating botulinum protease variants that can inhibit the release of neuropeptides and cytokines in neurons and immune cells, respectively. The goal is to create a new topical therapeutic...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846), will enable Duke University to develop a 3D skin model system to investigate interactions between the skin microbiome and skin cell populations. The $198,782 award, effective April 10, 2025 through March 31, 2027, will fund the creation of 3D reconstructed human epidermis (RHE)...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $343,904 to The Regents of the University of California, San Francisco to investigate transcriptional abnormalities in skin-resident T cells as potential biomarkers for atopic dermatitis in Asian and Hispanic genetic backgrounds. The research aims to validate an abnormal atopic T...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a novel peptide-based therapeutic agent called M10 for the treatment of skin fibrosis associated with systemic sclerosis (scleroderma). The $613,036 award to Fibrobiologics LLC aims to determine the antifibrotic activity of M10 in primary skin fibroblasts from scleroderma...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on defining and treating genetic abnormalities in psoriasis/atopic dermatitis-overlap dermatoses. The total award amount is $628,968.00 with a project period from June 20, 2025 to April 30, 2030. The awardee is The Regents of the University of California, San Francisco (UCSF), a prominent...
This federal Project Grant award, valued at $230,212 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), supports research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The goal of the research is to investigate how the immune system, specifically dendritic epidermal T cells (DETCs), drives functional heterogeneity in skin epithelial stem cells within and across different niches. The research will shed...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $595,117 to Vanderbilt University to develop carrier-free siRNA conjugates as disease-modifying osteoarthritis drugs. The project aims to (1) elucidate the mechanism of action of siRNA-L2 against MMP13 in osteoarthritis, (2) test new chemical modifications to improve joint retention...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $242,310 to Rockefeller University to investigate the long-term systemic consequences of type 2 skin inflammation on epithelial stem cells. The research aims to uncover how allergic type 2 inflammation impacts the functional responsiveness and epigenetic state of epithelial stem...
This Project Grant award of $176,148 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports a 5-year research and career development plan for Dr. Maxime Kinet at the University of California, San Francisco (UCSF). The goal of the research is to define the role of PI16-expressing fibroblasts in mouse and human fibrosing skin diseases. Dr. Kinet will use novel genetic...